CN103038253A - 作为用来稳定生物屏障的活性剂的肽 - Google Patents

作为用来稳定生物屏障的活性剂的肽 Download PDF

Info

Publication number
CN103038253A
CN103038253A CN2011800299272A CN201180029927A CN103038253A CN 103038253 A CN103038253 A CN 103038253A CN 2011800299272 A CN2011800299272 A CN 2011800299272A CN 201180029927 A CN201180029927 A CN 201180029927A CN 103038253 A CN103038253 A CN 103038253A
Authority
CN
China
Prior art keywords
seq
peptide
xib1
cell
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800299272A
Other languages
English (en)
Chinese (zh)
Inventor
彼得·佩策尔鲍尔
索尼娅·雷因格鲁贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XiberScience GmbH
Original Assignee
XiberScience GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XiberScience GmbH filed Critical XiberScience GmbH
Publication of CN103038253A publication Critical patent/CN103038253A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2011800299272A 2010-06-18 2011-06-17 作为用来稳定生物屏障的活性剂的肽 Pending CN103038253A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT10102010 2010-06-18
ATA1010/2010(4BA1010/2010-1) 2010-06-18
PCT/EP2011/060105 WO2011157819A2 (en) 2010-06-18 2011-06-17 Peptides as active agents to stabilize biological barriers

Publications (1)

Publication Number Publication Date
CN103038253A true CN103038253A (zh) 2013-04-10

Family

ID=44628513

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800299272A Pending CN103038253A (zh) 2010-06-18 2011-06-17 作为用来稳定生物屏障的活性剂的肽

Country Status (8)

Country Link
US (1) US9012403B2 (enExample)
EP (1) EP2582720B1 (enExample)
JP (1) JP5709985B2 (enExample)
CN (1) CN103038253A (enExample)
CA (1) CA2802635A1 (enExample)
ES (1) ES2486321T3 (enExample)
RU (1) RU2012157399A (enExample)
WO (1) WO2011157819A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108027366A (zh) * 2015-07-09 2018-05-11 米梅塔斯公司 屏障功能测量
CN112703009A (zh) * 2018-08-17 2021-04-23 宾夕法尼亚大学董事会 治疗急性肺损伤的组合物和方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2585097B1 (en) 2010-06-25 2018-09-26 Aston University Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
KR20230148844A (ko) * 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
US20220062391A1 (en) * 2019-01-16 2022-03-03 University Of Rochester Enhancing epithelial or endothelial barrier function
WO2021148763A1 (en) 2020-01-22 2021-07-29 Ucl Business Ltd Peptide inhibitors of guanine nucleotide exchange factor-h1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053250A1 (en) * 2001-03-05 2004-03-18 Tang Y. Tom Novel arginine-rich protein-like nucleic acids and polypeptides
CN1671742A (zh) * 2002-07-03 2005-09-21 塔博尔山圣拉弗尔基金中心 Hmgb1在治疗组织损伤和/或促进组织修复中的用途
US20060105982A1 (en) * 2000-04-25 2006-05-18 The Regents Of The University Of California Non-invasive gene targeting to ocular cells

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0350973B1 (de) 1983-09-26 1997-11-05 Udo Dr. Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
ES2362386T3 (es) 2007-06-21 2011-07-04 Technische Universität München Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105982A1 (en) * 2000-04-25 2006-05-18 The Regents Of The University Of California Non-invasive gene targeting to ocular cells
US20040053250A1 (en) * 2001-03-05 2004-03-18 Tang Y. Tom Novel arginine-rich protein-like nucleic acids and polypeptides
CN1671742A (zh) * 2002-07-03 2005-09-21 塔博尔山圣拉弗尔基金中心 Hmgb1在治疗组织损伤和/或促进组织修复中的用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MARION GROGER ET.AL.,: "Peptide Bβ15-42 Preserves Endothelial Barrier Function in Shock", 《PLOS ONE》, vol. 4, no. 4, 29 April 2009 (2009-04-29), pages 6 - 1, XP055009729, DOI: doi:10.1371/journal.pone.0005391 *
SANDRA CITI ET.AL.,: "The Tight Junction Protein Cingulin Regulates Gene Expression and RhoA Signaling", 《ANN. N.Y. ACAD. SCI.》, vol. 1165, 31 December 2009 (2009-12-31) *
UNIPROT DATABASE: "Q7X9P7", 《UNIPROT DATABASE》, 1 October 2003 (2003-10-01) *
UNIPROT DATABASE: "Q8GRW2", 《UNIPROT DATABASE》, 1 March 2003 (2003-03-01) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108027366A (zh) * 2015-07-09 2018-05-11 米梅塔斯公司 屏障功能测量
CN112703009A (zh) * 2018-08-17 2021-04-23 宾夕法尼亚大学董事会 治疗急性肺损伤的组合物和方法
CN112703009B (zh) * 2018-08-17 2024-06-11 宾夕法尼亚大学董事会 治疗急性肺损伤的组合物和方法

Also Published As

Publication number Publication date
WO2011157819A3 (en) 2012-02-23
EP2582720A2 (en) 2013-04-24
RU2012157399A (ru) 2014-07-27
US20130143791A1 (en) 2013-06-06
ES2486321T3 (es) 2014-08-18
WO2011157819A2 (en) 2011-12-22
JP2013529916A (ja) 2013-07-25
US9012403B2 (en) 2015-04-21
EP2582720B1 (en) 2014-05-21
CA2802635A1 (en) 2011-12-22
JP5709985B2 (ja) 2015-04-30

Similar Documents

Publication Publication Date Title
CN103038253A (zh) 作为用来稳定生物屏障的活性剂的肽
US9938320B2 (en) Peptides for promoting angiogenesis and use thereof
AU2020337111A1 (en) Q-ER peptide
Loo et al. Discovery of hyperstable noncanonical plant-derived epidermal growth factor receptor agonist and analogs
CN105579054A (zh) 预防或治疗左心室重塑的方法
Gimenez et al. Effect of intramuscular baculovirus encoding mutant hypoxia-inducible factor 1-alpha on neovasculogenesis and ischemic muscle protection in rabbits with peripheral arterial disease
WO2018166119A1 (zh) 一种多肽或其衍生物及其在制备治疗肿瘤的药物中的应用
US20060281670A1 (en) Compositions and methods for modulating angiogenesis
US9249185B2 (en) Peptides for promoting angiogenesis and an use thereof
CN108926713A (zh) 钙调磷酸酶调节蛋白1.4或其类似物在制备抑制肝癌的药物中的应用
CN109553660B (zh) 靶向rage胞浆内段接头slp76及其sam的用途
WO2000005356A1 (en) Methods and compositions for inhibition of angiogenesis
KR101721733B1 (ko) 혈관신생촉진용 펩타이드 및 이의 용도
US20090075893A1 (en) Inhibition of Angiogenesis by Neutrophil Alpha-Defensins
JP2019522041A (ja) 新規のペプチド及びペプチド模倣体
KR20160093637A (ko) 종양에 대한 직접적 억제 효과를 갖는 인터페론을 결정하는 방법 및 그의 용도
HK1184167A (en) Peptides as active agents to stabilize biological barriers
Pan et al. Myofibroblast-specific inhibition of ASPP1 alleviates myocardial fibrosis by enhancing p53 degradation
KR20240138585A (ko) Nampt 유래 펩타이드를 유효성분으로 포함하는 염증성 장 질환 개선, 예방 또는 치료용 조성물
CN117384257A (zh) 小分子多肽kp-4在制备治疗肾脏纤维化或慢性肾脏病的药物中的用途
Shen et al. Pin1 Regulates IL-5 Induced Eosinophil Polarization and Migration. Cells 2021, 10, 211
JP5555176B2 (ja) 医薬組成物及びその使用方法
CN101181627A (zh) 一种人亲和素蛋白在制备抗肝癌药物中的应用
WO2012013249A1 (en) Dentin matrix protein 1 (dmp1) for use in pharmaceutical compositions
CA3112175A1 (en) Peptides and medical uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1184167

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130410

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1184167

Country of ref document: HK